Clinical trial
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
NCT04047628
Study timeline
Study start (actual)2020-08-17Date precision: day
Registry last updated2026-09-16
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Relapsing Multiple Sclerosisunresolved
Relapsing Remitting Multiple Sclerosisunresolved
Secondary Progressive Multiple Sclerosisunresolved
Interventions
Sponsors & collaborators
Immune Tolerance Network (ITN)collaborator
PPD Development, LPcollaborator
Rho Federal Systems Division, Inc.collaborator
Mapped research locations
SeattleWashington, United States3New YorkNew York, United States1HoustonTexas, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1St LouisMissouri, United States1ClevelandOhio, United States1CincinnatiOhio, United States1PortlandOregon, United States1DurhamNorth Carolina, United States1MinneapolisMinnesota, United States1AuroraColorado, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04047628 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.